Pharmacogenomics and lung transplantation: Clinical implications

Pharmacogenomics Journal

Volumn 6, Issue 5, 2006, Pages 301-310

  Burckart, G J ^a   Hutchinson, I V ^a,b,c   Zeevi, A ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c National Institute of Transplantation Los Angeles   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BIOLOGICAL MARKER; CALCINEURIN; CHEMOKINE RECEPTOR CXCR3; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A5; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; METALLOPROTEINASE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; PROTEIN S 100; PROTEIN S 100A; RAPAMYCIN; STEROID; T LYMPHOCYTE ANTIBODY; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE NECROSIS; CARDIAC ALLOGRAFT VASCULOPATHY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VALIDATION PROCESS;

ALGORITHMS; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 33749250707     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500376     Document Type: Article

References (82)

1. Studer SM, Levy RD, McNeil K, Orens JB. Lung transplant outcomes: A review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Resp J 2004; 24: 674-685.
2. Trindade AJ, Palmer SM. Current concepts and controversies in lung transplantation. Resp Care Clin N Am 2004; 10: 427-447.
3. Arcasoy SM. Medical complications and management of lung transplant recipients. Resp Care Clin N Am 2004; 10: 505-529.
4. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G et al. Costimulation blockade with belatacept in renal transplantation [see comment]. N Engl J Med 2005; 353: 770-781.
5. Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seilar DA et al. A randomized trial of inhaled cyclosporine in lung transplant recipients. N Engl J Med 2006; 354: 141-150.
6. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41: 542-551.
7. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430.
8. MacPhee IAM, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.[see comment]. Am J Transplant 2004; 4: 914-919.
9. Clase CM, Mahalati K, Kiberd BA, Lawen JG, West KA, Fraser AD et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am J Transplant 2002; 2: 789-795.
10. van Gelder T, Hesselink DA, van Hest RM, Mathot RAA, van Schaik R. Pharmacogenetics in immunosuppressive therapy: The best thing since TDM? Ther Drug Monitor 2004; 26: 343-346.
11. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26: 180-185.
12. Huang W, Lin YS, McConn II DJ, Calamia JC, Totah RA, Isoherranen N et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004; 32: 1434-1445.
13. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3: 477-483.
14. Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 2004; 44: 135-140.
15. Hesselink DA, van Schaik RHN, van der Heiden IP, van der Werf M, Gregoor PJHS, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
16. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.[see comment]. Pharmacogenetics 2004; 14: 147-154.
17. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89-95.
18. Wang J, Zeevi A, McCurry K, Schuetz E, Zheng HX, Iacono A, McDade K et al. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transplant Immunol 2006; 15: 235-240.
19. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-1052.
20. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433.
21. Min DI, Ellingrod VL, Marsh S, McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004; 26: 524-528.
22. Hesselink DA, van Gelder T, van Schaik RHN, Balk AHMM, van der Heiden IP, van Dam T et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-556.
23. Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL et al. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109.
24. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595-603.
25. Potter JM, McWhinney BC, Sampson L, Hickman PE. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Ther Drug Monit 2004; 26: 408-414.
26. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dialysis Transplant 2003; 18: 2409-2414.
27. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999; 93: 1075-1085.
28. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ. A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 2000; 38: 1-11.
29. Donnenberg VS, Burckart GJ, Zeevi A, Griffith BP, Iacono A, McCurry KR et al. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection. Transplantation 2004; 77: 1699-1706.
30. Donnenberg VS, Burckart GJ, Griffith BP, Jain AB, Zeevi A, Berg AD. P-glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipients. J Clin Pharmacol 2001; 41: 1271-1279.
31. Yousem SA, Sartori D, Sonmez-Alpan E. Multidrug resistance in lung allograft recipients: Possible correlation with the development of acute and chronic rejection. J Heart Lung Transplant 1993; 12: 20-26.
32. Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transplant Immunol 2005; 14: 37-42.
33. Zheng HX, Burckart GJ, McCurry K, Webber S, Ristich J, Iacono A et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant 2004; 23: 541-546.
34. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63: 765-770.
35. Zheng HX, Webber SA, Zeevi A, Schuetz E, Zhang J, Lamba J et al. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 2004; 8: 551-557.
36. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-1511.
37. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661-674.
38. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003; 13: 675-682.
39. Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69: 308-316.
40. Sindhi R, Webber S, Venkataramanan R, McGhee W, Phillips S, Smith A et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001; 72: 851-855.
41. Awad MR, Webber S, Boyle G, Sturchioc C, Ahmed M, Martell J et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 2001; 20: 625-630.
42. Warle MC, Metselaar HJ, Hop WCJ, Tilanus HW. Cytokine gene polymorphisms and acute liver graft rejection: A meta-analysis. Liver Transplant 2005; 11: 19-26.
43. Azzawi M, Hasleton PS, Turner DM, Yonan N, Deiraniya AK, Sinnott PJ et al. Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients. Hum Immunol 2001; 62: 140-142.
44. Turner D, Grant SC, Yonan N, Sheldon S, Dyer PA, Sinnott PJ et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation 1997; 64: 776-779.
45. Sankaran D, Asderakis A, Ashraf S, Roberts IS, Short CD, Dyer PA et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999; 56: 281-288.
46. Pelletier R, Pravica V, Perrey C, Xia D, Ferguson RM, Hutchinson I et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 2000; 70: 674-680.
47. George S, Turner D, Reynard M, Navarrete C, Rizvi I, Fernando ON et al. Significance of cytokine gene polymorphism in renal transplantation. Transplant Proc 2001; 33: 483-484.
48. Bedi M, Postava LA, Murali S, MacGowan GA, Mathier M, Shears L et al. Effect of the TNF-alpha-promoter polymorphism on cardiac allograft rejection. J Heart Lung Transplant 2004; 23: 696-700.
49. Densem CG, Hutchinson IV, Yonan N, Brooks NH. Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. J Heart Lung Transplant 2001; 20: 1265-1273.
50. Abdallah AN, Cucchi-Mouillot P, Biteau N, Cassaigne A, Haras D, Iron A. Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. Eur J Immunogenet 1999; 26: 249-255.
51. Fernandes H, Koneru B, Fernandes N, Hameed M, Cohen MC, Raveche E et al. Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients. Transplantation 2002; 73: 1886-1891.
52. Mas VR, Fisher RA, Maluf DG, Archer KJ, Contos MJ, Mills SA et al. Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation. Clin Genet 2004; 65: 191-201.
53. Bathgate AJ, Pravica V, Perrey C, Therapondos G, Plevris JN, Hayes PC et al. The effect of polymorphisms in tumor necrosis factor-alpha, interieukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection [see comment]. Transplantation 2000; 69: 1514-1517.
54. Warle MC, Farhan A, Metselaar HJ, Hop WCj, Perrey C, Zondervan PE et al. Cytokine gene polymorphisms and acute human liver graft rejection. Liver Transplant 2002; 8: 603-611.
55. Jonsson JR, Hong C, Purdie DM, Hawley C, Isbel N, Butler M et al. Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. Liver Transplant 2001; 7: 255-263.
56. Jazrawi SF, Zaman A, Muhammad Z, Rabkin JM, Corless CL, Olyaei A et al. Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: A case control analysis of 210 donor-recipient pairs. Liver Transplant 2003; 9: 377-382.
57. Wramner LG, Norrby J, Hahn-Zoric M, Ahlmen J, Borjesson P-A, Carlstrom J et al. Impaired kidney graft survival is associated with the TNF-alpha genotype. Transplantation 2004; 78: 117-121.
58. Lu KC, Jaramillo A, Lecha RL, Schuessler RB, Aloush A, Trulock EP et al. Interleukin-6 and interferon-gamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2002; 74: 1297-1302.
59. Muller-Steinhardt M, Hartel C, Muller B, Kirchner H, Fricke L. The interleukin-6-174 promoter polymorphism is associated with long-term kidney allograft survival. Kidney Int 2002; 62: 1824-1827.
60. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-1020.
61. El-Gamel A, Awad MR, Hasleton PS, Yonan NA, Hutchinson JA, Campbell CS et al. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 1999; 18: 517-523.
62. Aziz T, Saad RA, Burgess M, Yonan N, Hasleton P, Hutchinson IV. Transforming growth factor beta and myocardial dysfunction following heart transplantation. Eur J Cardio-Thoracic Surg 2001; 20: 177-186.
63. Aziz T, Hasleton P, Hann AW, Yonan N, Deiraniya A, Hutchinson IV. Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation. J Thorac Cardiovasc Surg 2000; 119: 700-708.
64. El-Gamel A, Awad M, Sim E, Hasleton P, Yonan N, Egan J et al. Transforming growth factor-beta1 and lung allograft fibrosis. Eur J Cardio-Thorac Surg 1998; 13: 424-430.
65. Aziz TM, Burgess MI, Haselton PS, Yonan NA, Hutchinson IV. Transforming growth factor beta and diastolic left ventricular dysfunction after heart transplantation: Echocardiographic and histologic evidence. J Heart Lung Transplant 2003; 22: 663-673.
66. Densem CG, Hutchinson IV, Cooper A, Yonan N, Brooks NH. Polymorphism of the transforming growth factor-beta 1 gene correlates with the development of coronary vasculopathy following cardiac transplantation. J Heart Lung Transplant 2000; 19: 551-556.
67. el-Gamel A, Awad M, Yonan N, Keevil B, Egan J, Campbell C et al. Does cyclosporin promote the secretion of transforming growth factor-beta 1 following pulmonary transplantation? Transplant Proc 1998; 30: 1525-1527.
68. Lacha J, Hubacek JA, Potmesil P, Viklicky O, Malek I, Vitko S. TGF-beta 1 gene polymorphism in heart transplant recipients - effect on renal function. Ann Transplant 2001; 6: 39-43.
69. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999; 26: 1-3.
70. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000; 61: 863-866.
71. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus [see comment]. Am J Gastroenterol 2003; 98: 144-150.
72. Asderakis A, Sankaran D, Dyer P, Johnson RW, Pravica V, Sinnott PJ et al. Association of polymorphisms in the human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 2001; 71: 674-677.
73. Densem CG, Hutchinson IV, Yonan N, Brooks NH. Influence of IFN-gamma polymorphism on the development of coronary vasculopathy after cardiac transplantation. Ann Thorac Surg 2004; 77: 875-880.
74. Awad M, Pravica V, Perrey C, El Gamel A, Yonan N, Sinnott PJ et al. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999; 60: 343-346.
75. Dierksheide JE, Baiocchi RA, Ferketich AK, Roychowdhury S, Pelletier RP, Eisenbeis CF et al. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood 2005; 105: 1558-1565.
76. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-1249.
77. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260-264.
78. Strom TB. Rejection - more than the eye can see. N Engl J Med 2005; 353: 2394-2396.
79. Bowdish ME, Arcasoy SM, Wilt JS, Conte JV, Davis RD, Garrity ER et al. Surrogate markers and risk factors for chronic lung allograft dysfunction. Am J Transplant 2004; 4: 1171-1178.
80. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342-2351.
81. Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6: 150-160.
82. Keshavjee S, Trulock EP, Doyle RL, Davis RD, Golden JG, MucCurry KR et al. Immunoregulatory influences on peripheral blood gene expression in lung transplant patients: The Lung Allograft Rejection Gene Expression Observational (LARGO) study. IntSoc Heart Lung Transplant Annu Meeting. Madrid, Spain, April 5-8, 2006 (abstract).